This article is more than 5 years old. Information may no longer be current.
VIDEO: Understanding of genetics in AML, MDS help predict prognosis, response to treatment
Click Here to Manage Email Alerts
In this video with Healio.com, Rafael Bejar, MD, PhD, of the University of California, San Diego, discusses advances in understanding the genetics of myeloid malignancies, including acute myeloid leukemia and myelodysplastic syndrome.
Emerging information about the “genetic underpinnings” of AML can be used to predict prognosis and develop therapies. According to Bejar, an example of this is midostaurin, which demonstrated an overall survival benefit in patients with FLT3-mutated AML. “This is something that is likely to change the standard of care,” he said.
MDS “… has been largely explained now, in terms of genetics,” and information about mutations is used to determine prognosis and response to treatment. The WHO, which creates guidelines for classifying MDS, is revising its guidelines to “include a category for patients who have mutations of SF3B1,” according to Bejar. This gene is associated with the presence of ring sideroblasts and “… will allow us to make the diagnosis in patients whom otherwise would have been left without a diagnosis if they didn’t have sufficient ring sideroblasts to meet the old criteria,” he said.